Peripheral Blood Mononucler Cells (PBMNC) prodotte con sistema a filtrazione selettiva

HEMATRATE®  Blood Filtration System/Pall Celeris*

Pubblicazioni

1. Spaltro, G. et al. Characterization of the Pall Celeris system as a point-of-care device for therapeutic angiogenesis. Cytotherapy 17, 1302–1313 (2015).
2. De Angelis, B. et al. Limb Rescue: A New Autologous-Peripheral Blood Mononuclear Cells Technology in Critical Limb Ischemia and Chronic Ulcers. Tissue Eng. Part C Methods 21, 423–435 (2015).
3. Persiani, F. et al. Peripheral Blood Mononuclear Cells Therapy for Treatment of Lower Limb Ischemia in Diabetic Patients: A Single-Center Experience. Ann. Vasc. Surg. 53, 190–196 (2018).
4. Scatena, A.; Petruzzi, P.; Maioli, F.; Lucaroni, F.; Ambrosone, C.; Ventoruzzo, G.; Liistro, F.; Tacconi, D.; Filippi, M. Di; Attempati, N.; et al. Autologous Peripheral Blood Mononuclear Cells for Limb Salvage in Diabetic Foot Patients with No-Option Critical Limb Ischemia. J. Clin. Med. 10, 2213 (2021).
5. Rehak, L.; Giurato, L.; Meloni, M.; Panunzi, A.; Manti, G.M.; Uccioli, L. The Immune-Centric Revolution in the Diabetic Foot : Monocytes and Lymphocytes Role in Wound Healing and Tissue Regeneration — A Narrative Review. J. Clin. Med. 11, 889. (2022)
6. Zamboni, M. et al. PBMNCs Treatment in Critical Limb Ischemia and Candidate Biomarkers of Efficacy. Diagnostics 12, 1137 (2022).
7. Magenta, A., Florio, M. C., Ruggeri, M. & Furgiuele, S. Autologous cell therapy in diabetes-associated critical limb ischemia: from basic studies to clinical outcomes – REVIEW. Int. J. Mol. Med. 48, 1–18 (2020).
8. Bonanni, M. et al. Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction : Is the Immuno-Centric Revolution Ready for the Prime Time ? Biomedicines 10, 1091 (2022).
9. Terlizzese, G., Stubinski, R., Casini, A., Clerici, G. & Sangiorgi, G. A case report of pudendal arteries angioplasty with sirolimus drug-coated balloon and drug-eluting stent associated with intracavernous autologous peripheral blood mononuclear cells injection for untreatable vasculogenic erectile dysfunction. Eur. Hear. J. – Case Reports 5, 1–6 (2021).
10. Scala, P. et al. Stem Cell and Macrophage Roles in Skeletal Muscle Regenerative Medicine. Int. J. Mol. Sci. 221, 867 (2021).
11. Scala, P.; Lovecchio, J.; Lamparelli, E.P.; Vitolo, R.; Giudice, V.; Selleri, C.; Rehak, L.; Maffulli, N.; Porta, G. Della Myogenic commitment of human stem cells by myoblasts Co-culture : a static vs . a dynamic approach. Artif. Cells, Nanomedicine, Biotechnol. 50, 49–58. (2022)
12. Bellisi, M. et al. Autologous peripheral blood mononuclear cells for the treatment of lower extremity lymphedema : A preliminary report. Veins Lymphat. 10, 47–52 (2021).
13. Caravaggio, F., Antonelli, M. & Depalmi, F. Regenerative medicine: potential applications for foot and ankle disorders. Lo Scalpello – Otodi Educ. 35, 117–128 (2021).
14. Bucalossi, M. & Mariani, F. Mononucleate da sangue periferico autologhe da filtrazione selettiva per il trattamento delle lesioni croniche dell’arto inferiore: Risultati a 4 anni. Ital. J. Wound Care 5, 69 (2021).
15. Carella, S., Rossi, C., Ribuffo, D. & Onesti, M. The Use of Peripheral Blood-Mononuclear Cells in Scleroderma Patients : An observational preliminary study. J. Biomed. Res. Rev. 4, 22–31 (2021).
16. Chisari, E., Rehak, L., Khan, W. S. & Maffulli, N. Tendon healing in presence of chronic low-level inflammation: A systematic review. Br. Med. Bull. 132, 97–116 (2019).
17. Chisari, E., Rehak, L., Khan, W. S. & Maffulli, N. The role of the immune system in tendon healing: A systematic review. Br. Med. Bull. 133, 49–64 (2020).
18. Di Vieste, G., Formenti, I., Balduzzi, G., Masserini, B. & De Giglio, R. Use of autologous peripheral blood mononuclear cells in a case of diabetic foot. JAMD 22, 230–233 (2019).
19. Colonna, M. R. et al. Regenerative Approaches Regenerative in Wound Healing : New New Alternatives for Older Tools. in Wound Healing- New Insight into Ancient Challenges (ed. IntechOpen) 155–163 (Intech, 2016).
20. Trignano, E. et al. Combined Treatment of Diabetic Foot Ulcer with Tarsal Tunnel Release and Perilesional Injections of Peripheral Blood Mononuclear Cells. J. Am. Podiatr. Med. Assoc. 107, 171–174 (2017).
21. Del Deo, V., Fico, A., Marini, C., Senese, S. & Gasparini, G. In-Site Monocyte Implantation in Bone Grafting for Maxillary Atrophy Reconstruction: A Preliminary Observational Proof of Concept Study. Implant Dent. 27, 529–541 (2018).
P a g . 6 | 6 Mod. ST MC-SOL-03C/ Rev. 001 del 260722
22. Orlandi, C., Bondioli, E., Venturi, M. & Melandri, D. Preliminary observations of a new approach to tissue repair: Peripheral blood mononuclear cells in platelet-rich plasma injected into skin graft area. Exp. Dermatol. 27, 795–797 (2018).
23. Di Pardo, A. et al. Infusion of autologous-peripheral blood mononuclear cells : a new approach for limb salvage in patients with diabetes. in 7th International Diabetic Foot Congress Abu Dhabi International Diabetic Foot Congress Abu Dhabi 4-8 (2017).
24. Scatena A., Maioli F, Petruzzi P, Ventoruzzo G, Liistro F, Bolognese L, Ercolini L, R. L. Autologous Peripheral Blood Mononuclear Cells implant in a series of diabetic patients with critical limb ischemia not eligible for revascularization. in Association of Diabetic Foot Surgeon 3–4 (2017).
25. Johnson, C., Rodenberg, E., Record Ritchie, R. D. & Jaworek Berning, J. Filtered blood cell preparations can be tailored for clinical applications. Cytotherapy 20, S119 (2018).
26. Palermo Chiara, Sanfiorenzo Angelo, Trigona Cristina, Bernardini Giulia, V. P. Role of Monocytes in the Treatment of Chronic Limb Ischemia and “Hard to Heal” Ulcers. J. Vasc. Surg. 68, e119 (2018).
27. Giannace G, Guerrieri M W , Setacci C, B. D. Validity of Adjuvant Therapy in patients with lower limb critical ischemia. in ASCVTS – Moscow (2018).
28. Ascoli Marchetti A, Oddi FM, Orellana B, Ciattaglia R, Ippoliti A. The use of selective filtration of Mononucleated cells from peripheral blood in patients with vascular ulcers promotes the healing. A pilot study in a high volume vascular surgery center. ESVS – Valencia (2018)
29. Onesti MG, Carella S, R. D. L’utilizzo delle cellule mononucleate da sangue periferico in chirurgia plastica. in 68th SICPRE – Palermo (2019).
30. Scatena A., Maioli F, Petruzzi P, Ventoruzzo G, Liistro F, Bolognese L, Ercolini L, R. L. Does Autologous Peripheral Mononuclear Cells Implant Allow Foot Surgery in Diabetic Patients with Critical Limb Ischaemia not Eligible for Revascularization? Does Autologous Peripheral Mononuclear Cells Implant Allow Foot Surgery in Diabetic Patients with. in 8th International Symposium Diabetic Foot – IDF- The Hague Netherland (2019).
31. Panunzi A, Caravaggi CMF, Sganrazoli AB, Bertulessi A, Barmina F, Casartelli A, Ludovico O, Simonetti D, S. G. Studio clinico prospettico osservazionle sull’impiego di cellule mononucleate autologhe da sangue periferico (PB-MNC) nel trattamento di ulcere ischemiche non infette nei pazienti diabetici affetti da ischemia critica periferica non rivascolarizzabili. in VI Congresso Nazionale del Gruppo di Studio della Podopatia Diabetica (2019).
32. Massimiliano Walter Guerrieri, Domenico Benevento, Giovanni Giannace, G. A. & GianMarco de Donato, et al Validity of Adjuvant Therapy in patients with lower limb critical ischemia. in Journal of Vascular Surgery Supplement – Veith Symposium New York (2019).
33. Maioli F, Scatena A., Ventoruzzo G, Mazzitelli G, Petruzzi P, Ercolini L, R. L. L’utilizzo dei monociti autologhi nel piede diabetico con ischemia critica degli arti inferiori non rivascolarizzabile. in The Italian Journal of Vascular and Endovascular Surgery 24, 61 (2019).
34. Biasi, G. Buora A, Zani F, F. P. Terapia rigenerativa delle lesioni trofiche con cellule mononucleate da sangue periferico nell’ischemia critica. in The Italian Journal of Vascular and Endovascular Surgery 24, 61 (2019).
35. Ruggeri, M. et al. Terapia con cellule mononucleate da sangue periferico come adiuvante le rivascolarizzazioni endovascolari del diabetico: risultati preliminari del ROTARI. Ital. J. Vasc. Endovasc. Surg. 6, 49 (2019).
36. Caravaggi CMF, Panunzi Andrea, Sangalli E, S. G. Clinical outcome of autologous PB-MNC in treatment of non infected ischemic DFU (3C TUC) in non option CLI. in 6th World Union of Wound Healing Society Abu Dhabi March (2020).

Abstracts & Poster

  1. Di Pardo, A. et al. Infusion of autologous-peripheral blood mononuclear cells : a new approach for limb salvage in patients with diabetes. in 7th International Diabetic Foot Congress abu Dhabi International Diabetic Foot Congress Abu Dhabi 4-8 (2017).
  2. Scatena A., Maioli F, Petruzzi P, Ventoruzzo G, Liistro F, Bolognese L, Ercolini L, R. L. Autologous Peripheral Blood Mononuclear Cells implant in a series of diabetic patients with critical limb ischemia not eligible for revascularization. in Association of Diabetic Foot Surgeon 3–4 (Association of Diabetc Surgeons, 2017).
  3. Johnson, C., Rodenberg, E., Record Ritchie, R. D. & Jaworek Berning, J. Filtered blood cell preparations can be tailored for clinical applications. Cytotherapy 20, S119 (2018).
  4. Palermo Chiara, Sanfiorenzo Angelo, Trigona Cristina, Bernardini Giulia, V. P. Role of Monocytes in the Treatment of Chronic Limb Ischemia and “Hard to Heal” Ulcers. Vasc. Surg. 68, e119 (2018).
  5. Giannace G, Guerrieri M W , Setacci C, B. D. Validity of Adjuvant Therapy in patients with lower limb critical ischemia. in ASCVTS – Moscow (2018).
  6. Onesti MG, Carella S, R. D. L’utilizzo delle cellule mononucleate da sangue periferico in chirurgia plastica. in 68th SICPRE – Palermo (2019).
  7. Scatena A., Maioli F, Petruzzi P, Ventoruzzo G, Liistro F, Bolognese L, Ercolini L, R. L. Does Autologous Peripheral Mononuclear Cells Implant Allow Foot Surgery in Diabetic Patients with Critical Limb Ischaemia not Eligible for Revascularization? Does Autologous Peripheral Mononuclear Cells Implant Allow Foot Surgery in Diabetic Patients with. in 8th International Symposium Diabetic Foot – IDF- The Hague Netherland (2019).
  8. Panunzi A, Caravaggi CMF, Sganrazoli AB, Bertulessi A, Barmina F, Casartelli A, Ludovico O, Simonetti D, S. G. Studio clinico prospettico osservazionle sull’impiego di cellule mononucleate autologhe da sangue periferico (PB-MNC) nel trattamento di ulcere ischemiche non infette nei pazienti diabetici affetti da ischemia critica periferica non rivascolarizzabili. in VI Congresso Nazionale del Gruppo di Studio della Podopatia Diabetica (2019).
  9. Massimiliano Walter Guerrieri, Domenico Benevento, Giovanni Giannace, G. A. & GianMarco de Donato, G. P. . C. S. . Validity of Adjuvant Therapy in patients with lower limb critical ischemia. in Journal of Vascular Surgery Supplement – Veith Symposium New York (2019).
  10. Maioli F, Scatena A., Ventoruzzo G, Mazzitelli G, Petruzzi P, Ercolini L, R. L. L’utilizzo dei monociti autologhi nel piede diabetico con ischemia critica degli arti inferiori non rivascolarizzabile. in The Italian Journal of Vascular and Endovascular Surgery 24, 61 (2019).
  11. Biasi, G. Buora A, Zani F, F. P. Terapa rigenerativa delle lesioni trofiche con cellule mononucleate da sangue periferico nell’ischemia critica. in The Italian Journal of Vascular and Endovascular Surgery 24, 61 (2019).
  12. Ruggeri, M. et al. Terapia con cellule mononucleate da sangue periferico come adiuvante le rivascolarizzazioni endovascolari del diabetico: risultati preliminari del ROTARI. . J. Vasc. Endovasc. Surg. 6, 49 (2019).
  13. Caravaggi CMF, Panunzi Andrea, Sangalli E, S. G. Clinical outcome of autologous PB-MNC in treatment of non infected ischemic DFU (3C TUC) in non option CLI. in 6th World Union of Wound Healing Societes  Abu Dhabi March (2020).

* I dispositivi medici Pall Celeris® e Cook Regentec Hematrate® sono prodotti da Pall Medical presso lo stabilimento di Pall Medemblik (NL), sono entrambi DM marchiati CE da Pall Sarl e sono equivalenti in impiego, classificazione DM, materiali, sterilizzazione e prestazioni.

Torna in alto